Correction: Regulatory Considerations Toward Orphan Drug Designation and Orphan Drug Exclusivity in the United States and European Union: Structural Similarity, Clinical Superiority/Significant Benefit, and Case Studies.

Autor: Roberts SW; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark. osrb@novonordisk.com., Elvang TLB; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Syed L; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Samuelsen MB; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Arp-Hansen EL; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Nielsen HK; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Lund IK; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Dünweber DL; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Listov-Saabye N; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Bjørn-Larsen D; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Hjelmsmark A; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark., Mikkelsen TA; Regulatory Affairs, Novo Nordisk A/S, Vandtårnsvej 114, 2860, Søborg, Denmark.
Jazyk: angličtina
Zdroj: Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2023 Mar; Vol. 57 (2), pp. 396-398.
DOI: 10.1007/s43441-022-00487-w
Databáze: MEDLINE
Externí odkaz: